Effects of the selective adenosine A2A receptor antagonist, SCH 412348, on the parkinsonian phenotype of MitoPark mice

European Journal of Pharmacology

Volumn 728, Issue 1, 2014, Pages 31-38

  Smith, Karen M ^a   Browne, Susan E ^a   Jayaraman, Srinivasan ^a   Bleickardt, Carina J ^a   Hodge, Lisa M ^a   Lis, Edward ^a   Yao, Leon ^a   Rittle, Sunday L ^a   Innocent, Nathalie ^a   Mullins, Deborra E ^a   Boykow, George ^a   Reynolds, Ian J ^a   Hill, David ^a   Parker, Eric M ^a   Hodgson, Robert A ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

A2A receptor antagonist; Locomotor activity; MitoPark mouse; Movement disorder; Parkinson's disease

Indexed keywords

ADENOSINE A2A RECEPTOR ANTAGONIST; SCH 412348; UNCLASSIFIED DRUG; (7-(2-(4-DIFLUOROPHENYL)-1-PIPERAZINYL)ETHYL)-2-(2-FURANYL)-7H-PYRAZOLO(4,3-E)(1,2,4)TRIAZOLO(1,5-C)PYRIMIDIN-5-AMINE; 4 AMINOBUTYRIC ACID; ADENOSINE A2 RECEPTOR ANTAGONIST; ADENOSINE A2A RECEPTOR; ANTIPARKINSON AGENT; PROTEIN BINDING; PYRIMIDINE DERIVATIVE; TRIAZOLE DERIVATIVE;

ACUTE DRUG ADMINISTRATION; AGE; AKINESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRADYKINESIA; CELL LOSS; CONTROLLED STUDY; DISEASE SEVERITY; DOPAMINERGIC NERVE CELL; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SCREENING; FEMALE; GLOBUS PALLIDUS; LOCOMOTION; MALE; MITOPARK MOUSE; MOUSE; MOUSE STRAIN; NONHUMAN; PARKINSONISM; PHENOTYPE; PRIORITY JOURNAL; ANIMAL; CHEMICALLY INDUCED; DOSE RESPONSE; DRUG EFFECTS; HYPOKINESIA; INBRED MOUSE STRAIN; METABOLISM; MOTOR ACTIVITY; PARKINSONIAN DISORDERS; PATHOPHYSIOLOGY; ROTAROD TEST;

ADENOSINE A2 RECEPTOR ANTAGONISTS; ANIMALS; ANTIPARKINSON AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; GAMMA-AMINOBUTYRIC ACID; GLOBUS PALLIDUS; HYPOKINESIA; MALE; MICE; MICE, INBRED STRAINS; MOTOR ACTIVITY; PARKINSONIAN DISORDERS; PROTEIN BINDING; PYRIMIDINES; RECEPTOR, ADENOSINE A2A; ROTAROD PERFORMANCE TEST; TRIAZOLES;

EID: 84896729308     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2014.01.052     Document Type: Article

References (37)

1. C.J. Bleickardt, A.L. Lashomb, C.E. Merkel, and R.A. Hodgson Adenosine A(2A) receptor antagonists do not disrupt rodent prepulse inhibition: an improved side effect profile in the treatment of Parkinson's disease Parkinsons Dis. 2012 2012 591094
2. F. Calon, M. Morissette, A.H. Rajput, O. Hornykiewicz, P.J. Bédard, and T. Di Paolo Changes of GABA receptors and dopamine turnover in the postmortem brains of parkinsonians with levodopa-induced motor complications Mov. Disord. 18 2003 241 253 (Pubitemid 36410820)
3. J.F. Chen, P.K. Sonsalla, F. Pedata, A. Melani, M.R. Domenici, P. Popoli, J. Geiger, L.V. Lopes, and A. de Mendonça Adenosine A2A receptors and brain injury: broad spectrum of neuroprotection, multifaceted actions and "fine tuning" modulation Prog. Neurobiol. 83 2007 310 331 (Pubitemid 350119825)
4. J.B. Chen, E.M. Liu, T.R. Chern, C.W. Yang, C.I. Lin, N.K. Huang, Y.L. Lin, Y. Chem, J.H. Lin, and J.M Fang Design and synthesis of novel dual-action compounds targeting the adenosine A(2A) receptor and adenosine transporter for neuroprotection ChemMedChem 6 2011 1390 1400
5. M.I. Ekstrand, and D. Galter The MitoPark mouse - an animal model of Parkinson's disease with impaired respiratory chain function in dopamine neurons Parkinsonism Relat. Disord. 15 Suppl. 3 2009 S185 S188
6. K. Fuxe, D. Marcellino, S. Genedani, and L. Agnati Adenosine A(2A) receptors, dopamine D(2) receptors and their interactions in Parkinson's disease Mov. Disord. 22 2007 1990 2017
7. D. Galter, K. Pernold, T. Yoshitake, E. Lindqvist, B. Hoffer, J. Kehr, N.G. Larsson, and L. Olson MitoPark mice mirror the slow progression of key symptoms and l-DOPA response in Parkinson's disease Genes Brain Behav. 9 2010 173 181
8. C.H. Good, A.F. Hoffman, B.J. Hoffer, V.I. Chefer, T.S. Shippenberg, C.M. Bäckman, N.G. Larsson, L. Olson, S. Gellhaar, D. Galter, and C.R. Lupica Impaired nigrostriatal function precedes behavioral deficits in a genetic mitochondrial model of Parkinson's disease FASEB J. 25 2011 1333 1344
9. L. Halldner, G. Lozza, K. Lindström, and B.B. Fredholm Lack of tolerance to motor stimulant effects of a selective adenosine A(2A) receptor antagonist Eur. J. Pharmacol. 406 2000 345 354
10. R.A. Hauser, J.P. Hubble, D.D. Truong Istradefylline US-001 Study Group Randomized trial of adenosine A(2A) receptor antagonist istradefylline in advanced PD Neurology 61 2003 297 303 (Pubitemid 36975955)
11. R.A. Hauser Future treatments for Parkinson's disease: surfing the PD pipeline Int. J. Neurosci. 121 Suppl. 2 2011 53 62
12. B.D. Hettinger, A. Lee, J. Lindem, and D.L. Rosin Ultrastructural localization of adenosine A2A receptors suggests multiple cellular sites for modulation of GABAergic neurons in rat striatum J. Comp. Neurol. 431 2001 331 346 (Pubitemid 32115298)
13. P. Hickey, and M. Stacy Adenosine A2A antagonists in Parkinson's disease: what's next? Curr. Neurol. Neurosci. Rep. 12 2012 376 385
14. G.A Higgins, ME Grzelak, A.J Pond, M.E Cohen-Williams, R.A Hodgson, and G.B. Varty The effect of caffeine to increase reaction time in the rat during a test of attention is mediated through antagonism of adenosine A2A receptors Behav. Brain Res. 185 2007 32 42 (Pubitemid 47559085)
15. R.A. Hodgson, R. Bertorelli, G.B. Varty, J.E. Lachowicz, A. Forlani, S. Fredduzzi, M.E. Cohen-Williams, G.A. Higgins, F. Impagnatiello, E. Nicolussi, L.E. Parra, C. Foster, Y. Zhai, B.R. Neustadt, A.W. Stamford, E.M. Parker, A. Reggiani, and J.C. Hunter Characterization of the potent and highly selective A2A receptor antagonists preladenant and SCH 412348 [7-[2-[4-2,4-difluorophenyl] -1-piperazinyl]ethyl]-2-(2-furanyl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c] pyrimidin-5-amine] in rodent models of movement disorders and depression J. Pharmacol. Exp. Ther. 330 2009 294 303
16. R.A. Hodgson, P.J. Bedard, G.B. Varty, T.M. Kazdoba, T. Di Paolo, M.E. Grzelak, A.J. Pond, A. Hadjtahar, N. Belanger, L. Gregoire, A. Dare, B.R. Neustadt, A.W. Stamford, and J.C. Hunter Preladenant, a selective A(2A) receptor antagonist, is active in primate models of movement disorders Exp. Neurol. 225 2010 384 390
17. K.A. Jacobson, and Z.G. Gao Adenosine receptors as therapeutic targets Nat. Rev. Drug Discovery 5 2006 247 264 (Pubitemid 43336037)
18. T. Kanda, M.J. Jackson, L.A. Smith, R.K. Pearce, J. Nakamura, H. Kase, Y. Kuwana, and P. Jenner Combined use of the adenosine A(2A) antagonist KW-6002 with l-DOPA or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys Exp. Neurol. 162 2000 321 327 (Pubitemid 30217727)
19. M. Karcz-Kubicha, K. Antoniou, A. Terasmaa, D. Quarta, M. Solinas, Z. Justinova, A. Pezzola, R. Reggio, C.E Müller, K. Fuxe, S.R Goldberg, P. Popoli, and S. Ferré Involvement of adenosine A1 and A2A receptors in the motor effects of caffeine after its acute and chronic administration Neuropsychopharmacology 28 2003 1281 1291 (Pubitemid 41070898)
20. A. Lees Alternatives to levodopa in the initial treatment of early Parkinson's disease Drugs Aging 22 2005 731 740 (Pubitemid 41242117)
21. E. Le Poul, C. Boléa, F. Girard, S. Poli, D. Charvin, B. Campo, J. Bortoli, A. Bessif, B. Luo, A.J. Koser, L.M. Hodge, K.M. Smith, A.G. DiLella, N. Liverton, F. Hess, S.E. Browne, and I.J. Reynolds A potent and selective metabotropic glutamate receptor 4 positive allosteric modulator improves movement in rodent models of Parkinson's disease J. Pharmacol. Exp. Ther. 343 2012 167 177
22. X. Li, K.K Blizzard, Z. Zeng, A.C DeVries, P.D Hurn, and L.D. McCullough Chronic behavioral testing after focal ischemia in the mouse: functional recovery and the effects of gender Exp. Neurol. 187 2004 94 104 (Pubitemid 38470016)
23. D. Marcellino, E. Lindqvist, M. Schneider, C.E. Müller, K. Fuxe, L. Olson, and D. Galter Chronic A2A antagonist treatment alleviates parkinsonian locomotor deficiency in MitoPark mice Neurobiol. Dis. 40 2010 460 466
24. B.R. Neustadt, J. Hao, N. Lindo, W.J. Greenlee, A.W. Stamford, D. Tulshian, E. Ongini, J. Hunter, A. Monopoli, R. Bertorelli, C. Foster, L. Arik, J. Lachowicz, K. Ng, and K.I. Feng Potent, selective, and orally active adenosine A2A receptor antagonists: arylpiperazine derivatives of pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines Bioorg. Med. Chem. Lett. 17 2007 1376 1380 (Pubitemid 46240836)
25. M. Ochi, K. Koga, M. Kurokawa, H. Kase, J. Nakamura, and Y. Kuwana Systemic administration of adenosine A(2A) receptor antagonist reverses increased GABA release in the globus pallidus of unilateral 6-hydroxydopamine- lesioned rats: a microdialysis study Neuroscience 100 2000 53 62 (Pubitemid 30670301)
26. S. Perez-Loret, M.V. Rey, L. Ratti, and O. Rascol Pramipexole for the treatment of early Parkinson's disease Expert Rev. Neurother. 11 2011 925 935
27. A. Pinna, S. Fenu, and M. Morelli Motor stimulant effects of the adenosine A2A receptor antagonist SCH 58261 do not develop tolerance after repeated treatments in 6-hydroxydopamine-lesioned rats Synapse 39 2001 233 238 (Pubitemid 32099678)
28. M. Saki, K. Yamada, E. Koshimura, K. Sasaki, and T. Kanda In vitro pharmacological profile of the A2A receptor antagonist istradefylline Naunyn. Schmiedebergs Arch. Pharmacol. 386 2013 963 972
29. M.A. Schwarzschild Adenosine A2A antagonists as neurotherapeutics: crossing the bridge Prog. Neurobiol. 83 2007 261 262 (Pubitemid 350110607)
30. R.E. See, and W.J. Berglink Decreased pallidal GABA following reverse microdialysis with clozapine, but not haloperidol Neuroreport 12 2001 3655 3658 (Pubitemid 33107380)
31. U. Shah, and R. Hodgson Recent progress in the discovery of adenosine A(2A) receptor antagonists for the treatment of Parkinson's disease Curr. Opin. Drug Discov. Dev. 13 2010 466 480
32. S. Shiozaki, S. Ichikawa, J. Nakamura, S. Kitamura, K. Yamada, and Y. Kuwana Actions of adenosine A2A receptor antagonist KW-6002 on drug-induced catalepsy and hypokinesia caused by reserpine or MPTP Psychopharmacology (Berl) 147 1999 90 95 (Pubitemid 30010028)
33. S. Tanganelli, K. Sandager Nielsen, L. Ferraro, T. Antonelli, J. Kehr, R. Franco, S. Ferré, L.F. Agnati, K. Fuxe, and J. Scheel-Krüger Striatal plasticity at the network level: focus on adenosine A2A and D2 interactions in models of Parkinson's disease Parkinsonism Relat. Disord. 10 2004 273 280 (Pubitemid 38757807)
34. E. Tronci, N. Simola, F. Borsini, N. Schintu, L. Frau, P. Carminati, and M. Morelli Characterization of the antiparkinsonian effects of the new adenosine A2A receptor antagonist ST1535: acute and subchronic studies in rats Eur. J. Pharmacol. 566 2007 94 102 (Pubitemid 46782796)
35. J.S. Valadis, V.L. Batalha, D.G. Ferreira, R. Gomes, J.E. Coelho, A.M. Sebastião, M.J. Diógenes, and L.V. Lopes Neuroprotection afforded by adenosine A2A receptor blockade is modulated by corticotrophin-releasing factor (CRF) in glutamate injured cortical neurons J. Neurochem. 123 2012 1030 1040
36. K. Varani, F. Vincenzi, A. Tosi, S. Gessi, I. Casetta, P. Granieri, Fazio, E. Leung, S. MacLennan, E. Granieri, and P.A. Borea A2A adenosine receptor overexpression and functionality, as well as TNF-alpha levels, correlate with motor symptoms in Parkinson's disease FASEB J. 24 2010 587 598
37. G.B. Varty, R.A. Hodgson, A.J. Pond, M.E. Grzelak, E.M. Parker, and J.C. Hunter The effects of adenosine A2A receptor antagonists on haloperidol-induced movement disorders in primates Psychopharmacology (Berl) 200 2008 393 401